BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38561515)

  • 21. Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities.
    Hirmas N; Hamacher R; Sraieb M; Ingenwerth M; Kessler L; Pabst KM; Barbato F; Lueckerath K; Kasper S; Nader M; Schildhaus HU; Kesch C; von Tresckow B; Hanoun C; Hautzel H; Aigner C; Glas M; Stuschke M; Kümmel S; Harter P; Lugnier C; Uhl W; Niedergethmann M; Hadaschik B; Grünwald V; Siveke JT; Herrmann K; Fendler WP
    J Nucl Med; 2023 May; 64(5):711-716. PubMed ID: 36581374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.
    Moon ES; Ballal S; Yadav MP; Bal C; Van Rymenant Y; Stephan S; Bracke A; Van der Veken P; De Meester I; Roesch F
    Am J Nucl Med Mol Imaging; 2021; 11(6):476-491. PubMed ID: 35003886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biodistribution, pharmacokinetics, dosimetry of [
    Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Tripathi M; ArunRaj ST; Sarswat S; Bal C
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1915-1931. PubMed ID: 33244617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Head-to-head Intra-individual Comparison of [
    Novruzov E; Dendl K; Ndlovu H; Choyke PL; Dabir M; Beu M; Novruzov F; Mehdi E; Guliyev F; Koerber SA; Lawal I; Niegisch G; Debus J; Haberkorn U; Sathekge M; Giesel FL
    Mol Imaging Biol; 2022 Aug; 24(4):651-658. PubMed ID: 35349039
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Dendl K; Koerber SA; Finck R; Mokoala KMG; Staudinger F; Schillings L; Heger U; Röhrich M; Kratochwil C; Sathekge M; Jäger D; Debus J; Haberkorn U; Giesel FL
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4089-4100. PubMed ID: 34050777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First Clinical Experience With [68Ga]Ga-FAPI-46-PET/CT Versus [18F]F-FDG PET/CT for Nodal Staging in Cervical Cancer.
    Wegen S; Roth KS; Weindler J; Claus K; Linde P; Trommer M; Akuamoa-Boateng D; van Heek L; Baues C; Schömig-Markiefka B; Schomäcker K; Fischer T; Drzezga A; Kobe C; Köhler C; Marnitz S
    Clin Nucl Med; 2023 Feb; 48(2):150-155. PubMed ID: 36607364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility of [
    Unterrainer LM; Lindner S; Eismann L; Casuscelli J; Gildehaus FJ; Bui VN; Albert NL; Holzgreve A; Beyer L; Todica A; Brendel M; Cyran CC; Karl A; Stief CG; Ledderose ST; Unterrainer M; Bartenstein P; Wenter V; Kretschmer A
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3571-3580. PubMed ID: 35325283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.
    Zhang P; Xu M; Ding J; Chen J; Zhang T; Huo L; Liu Z
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1985-1996. PubMed ID: 34746969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual targeting PET tracer [
    Wang R; Jakobsson V; Wang J; Zhao T; Peng X; Li B; Xue J; Liang N; Zhu Z; Chen X; Zhang J
    Theranostics; 2023; 13(9):2979-2992. PubMed ID: 37284441
    [No Abstract]   [Full Text] [Related]  

  • 30. Superior Tumor Detection for
    Pabst KM; Trajkovic-Arsic M; Cheung PFY; Ballke S; Steiger K; Bartel T; Schaarschmidt BM; Milosevic A; Seifert R; Nader M; Kessler L; Siveke JT; Lueckerath K; Kasper S; Herrmann K; Hirmas N; Schmidt HH; Hamacher R; Fendler WP
    J Nucl Med; 2023 Jul; 64(7):1049-1055. PubMed ID: 37024301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FAPI-74 PET/CT Using Either
    Giesel FL; Adeberg S; Syed M; Lindner T; Jiménez-Franco LD; Mavriopoulou E; Staudinger F; Tonndorf-Martini E; Regnery S; Rieken S; El Shafie R; Röhrich M; Flechsig P; Kluge A; Altmann A; Debus J; Haberkorn U; Kratochwil C
    J Nucl Med; 2021 Feb; 62(2):201-207. PubMed ID: 32591493
    [No Abstract]   [Full Text] [Related]  

  • 32. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
    Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
    Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Head-to-head intra-individual comparison of biodistribution and tumor uptake of
    Giesel FL; Kratochwil C; Schlittenhardt J; Dendl K; Eiber M; Staudinger F; Kessler L; Fendler WP; Lindner T; Koerber SA; Cardinale J; Sennung D; Roehrich M; Debus J; Sathekge M; Haberkorn U; Calais J; Serfling S; Buck AL
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4377-4385. PubMed ID: 34137945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical translational evaluation of Al
    Wang S; Zhou X; Xu X; Ding J; Liu S; Hou X; Li N; Zhu H; Yang Z
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4259-4271. PubMed ID: 34165601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
    Wen X; Xu P; Shi M; Liu J; Zeng X; Zhang Y; Shi C; Li J; Guo Z; Zhang X; Khong PL; Chen X
    Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657
    [No Abstract]   [Full Text] [Related]  

  • 36. Performance and Prospects of [
    Borgonje PE; Andrews LM; Herder GJM; de Klerk JMH
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of
    Röhrich M; Naumann P; Giesel FL; Choyke PL; Staudinger F; Wefers A; Liew DP; Kratochwil C; Rathke H; Liermann J; Herfarth K; Jäger D; Debus J; Haberkorn U; Lang M; Koerber SA
    J Nucl Med; 2021 Jun; 62(6):779-786. PubMed ID: 33097632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
    Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and Development of
    Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
    J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA
    Moon ES; Elvas F; Vliegen G; De Lombaerde S; Vangestel C; De Bruycker S; Bracke A; Eppard E; Greifenstein L; Klasen B; Kramer V; Staelens S; De Meester I; Van der Veken P; Rösch F
    EJNMMI Radiopharm Chem; 2020 Jul; 5(1):19. PubMed ID: 32728930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.